ReviewBiosensors2025
Multiplexed Optical Nanobiosensing Technologies for Disease Biomarker Detection.
Review in Biosensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Microfluidic-assisted metal nanoparticle synthesis: emerging trends toward optical sensing applications.RSC advances · 2026Review
- Smartphone-based preeclampsia diagnosis through detection of dual biomarkers - nephrin and podocalyxin.Biosensors & bioelectronics · 2026Article
- Graphene Oxide (GO) and Gold Nanoparticles (AuNP) Facilitated Electrochemical Biosensing for Lung Cancer Diagnosis.Diagnostics (Basel, Switzerland) · 2026Review
- Advancements in Nanomaterial-Based Biosensors for Neuropsychiatric and Neurodegenerative Diagnostics: From Biomarker Discovery to Clinical Translation.Biosensors · 2026Review
- Review
- Evolution of Biosensors and Current State-of-the-Art Applications in Diabetes Control.Biosensors · 2026Review
- Nanomaterial-enhanced biosensors for traumatic brain injury biomarker detection: a review of analytical performance, machine learning integration, clinical validation, and point-of-care translation.Frontiers in neurology · 2026Review
- Design of Nanostructured Enzyme Immobilized Platforms for Precise Diagnosis and Treatment of Endocrine Disease: An Updated Review.International journal of nanomedicine · 2026Review
- Localized surface plasmon resonance-based point-of-care testing for pediatric sepsis.Frontiers in pediatrics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Most biomarkers exhibit abnormal expression in more than one disease, making conventional single-biomarker detection strategies prone to false-negative results. Detecting multiple biomarkers associated with a single disease can therefore substantially improve diagnostic accuracy. Accordingly, recent research has focused on precise multiplex detection, leading to the development of sensors employing various readout methods, including electrochemical, fluorescence, Raman, and colorimetric approaches. This review focuses on optical sensing applications, such as fluorescence, Raman spectroscopy, and colorimetry, which offer rapid and straightforward detection and are well suited for point-of-care testing (POCT). These optical sensors exploit nanoscale phenomena derived from the intrinsic properties of nanomaterials, including metal-enhanced fluorescence (MEF), Förster resonance energy transfer (FRET), and surface-enhanced Raman scattering (SERS), which can be tailored through modifications in material type and structure. We summarize the types and properties of commonly used nanomaterials, including plasmonic and carbon-based nanoparticles, and provide a comprehensive overview of recent advances in multiplex biomarker detection. Furthermore, we address the potential of these nanosensors for clinical translation and POCT applications, highlighting their relevance for next-generation disease diagnostic platforms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.